



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73545

Title: PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06235235

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Nepal

Author's Country/Territory: China

Manuscript submission date: 2022-01-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-10 08:05

Reviewer performed review: 2022-01-11 16:42

Review time: 1 Day and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Core tip: Is this sentence complete? “The general situation of the patient after surgery can be.” Introduction: 1. Your citation starts directly from number 4? Then goes to number 1 and then to 7. 2. Maintain uniformity and start from 1 in ascending order. Case Presentation: 1. A 30-year-old man's bowel habits change over a year. Please elaborate 2. 2021-05-26 Colonoscopy found a mass approximately..... What is 2021-05-26? It seems to be date, but modify sentence structure. It is a good case report. However there are many errors in writing without proper citation and referencing. Without correcting these, it should not be published. Read your article at least once from top to bottom before sending to journals.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73545

Title: PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02944288

Position: Editorial Board

Academic degree: MD

Professional title: Assistant Professor, Lecturer, Surgeon

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2022-01-09

Reviewer chosen by: Qi-Gu Yao (Online Science Editor)

Reviewer accepted review: 2022-01-14 02:58

Reviewer performed review: 2022-01-14 03:52

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

manuscript could be published



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73545

Title: PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03604107

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Albania

Author's Country/Territory: China

Manuscript submission date: 2022-01-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-09 15:19

Reviewer performed review: 2022-01-16 14:39

Review time: 6 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input type="checkbox"/>] Anonymous [<input checked="" type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The paper is interesting and very well written. All over, I am preoccupied only with a detail which is repeated: there are several examinations (CT, biopsies) etc. that are mentioned by date; for example: abdominal CT (2021-11-17) --- but a lot more. This can lead to the identification of the patient; which is ethically not good. I understand you have the written consent, but better to avoid irrelevant details (such as dates of examinations) and just follow a chronological description of the entire course of the disease. A few grammatical errors need to be address (for example, inmpotence)....



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73545

Title: PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03478911

Position: Associate Editor

Academic degree: PhD

Professional title: Chief Technician, Executive Vice President, Research Assistant Professor

Reviewer’s Country/Territory: South Korea

Author’s Country/Territory: China

Manuscript submission date: 2022-01-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-09 12:32

Reviewer performed review: 2022-01-17 06:36

Review time: 7 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a good case for CRC treatment by a PD-1 inhibitor in combination with fruquintinib as neoadjuvant therapy. However, it needs to supplement the following issues. 1. Demographic and etiological information should be provided in a separate table. 2. A clinical view should be stated about the unresectable reason for the lesion. 3. It would be insufficient evidence that feature for MSI-H was the only reason for suggesting a combination treatment with a PD-1 inhibitor and fruquintinib. MSI-H patients have characteristics related to high VEGF expression, and the use of fruquintinib to suppress this may be a good rationale for selecting the therapeutics. The rationale should be supplemented where appropriate paragraph. 4. What advantages can be emphasized compared to the existing neoadjuvant therapeutics such as FOLFIRI, FOLFOX, or CAPOX should be described.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73545

Title: PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03604107

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Albania

Author's Country/Territory: China

Manuscript submission date: 2022-01-09

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2022-03-17 16:47

Reviewer performed review: 2022-03-18 15:52

Review time: 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The paper is interesting and worthy publishing; but still my concern about the publication of irrelevant details leading to potentially identification of the patient remains. Some unnecessary dates are still included in the revised version: On May 26, 2021, the patient underwent a colonoscopy. 2021-05 Whole abdominal CT Another abdominal CT was obtained on 2021-07 _____ I see no scientific reason why you should include the dates of the examinations ?